Boehringer Ingelheim Invests $50M in Click Therapeutics to Commercialize CT‑155 Schizophrenia Digital Therapeutic

Why It Matters

The deal gives Click end‑to‑end control of a breakthrough therapy for a symptom cluster lacking FDA‑approved drugs, positioning it to capture a high‑value segment of the mental‑health market and signaling pharma’s growing confidence in digital therapeutics.

Key Takeaways

• Boehringer transfers all commercial rights for CT‑155 to Click
• CT‑155 achieved 6.8‑point improvement in negative symptoms, 62% gain
• FDA Breakthrough Device Designation earned in 2024 for CT‑155
• Phase III CONVOKE trial showed lower adverse events than control

Pulse Analysis

The mental‑health sector has long struggled to address the "negative" symptoms of schizophrenia—lack of motivation, emotional blunting, and social withdrawal—that conventional antipsychotics leave untouched. Digital therapeutics, which blend evidence‑based psychosocial interventions with software platforms, are emerging as a viable solution. Click Therapeutics' CT‑155 leverages interactive modules to re‑engage patients, and its recent FDA Breakthrough Device Designation underscores regulatory openness to novel, data‑driven treatments that fill clinical gaps.

Boehringer Ingelheim’s decision to hand over commercial and marketing rights to Click, coupled with a $50 million Series D infusion, reflects a strategic pivot toward asset‑light models. By funding the commercialization engine rather than retaining direct sales responsibilities, Boehringer can focus on drug discovery while tapping into Click’s digital expertise. This partnership also signals to other pharmaceutical players that investing in digital platforms can accelerate time‑to‑market for high‑need therapies, potentially reshaping traditional go‑to‑market frameworks.

Market analysts estimate the global schizophrenia therapeutics market will exceed $15 billion by 2030, yet no product currently targets negative symptoms. CT‑155’s Phase III results—showing a 62% relative improvement and a lower adverse‑event rate—position it to capture a sizable share of this untapped segment. If commercialization proceeds smoothly, insurers may adopt the therapy as a cost‑effective adjunct to medication, driving broader adoption of digital health solutions across psychiatric care. The success of CT‑155 could catalyze further investment in digital therapeutics aimed at complex neuropsychiatric conditions.

Deal Summary

Boehringer Ingelheim has made a $50 million Series D strategic investment in Click Therapeutics, transferring all commercial and marketing rights for the CT‑155 digital therapeutic targeting negative symptoms of schizophrenia. The funding will support commercialization and includes undisclosed dedicated commercial funding. The deal was announced on April 9, 2026.